



TRIMURTHI LIMITED
5-8-354/1106, Office No. 1106,
Ratna Block, Raghav Ratna Towers,
Chirag Ali Lane, Abid,
Hyderabad, Telangana - 500 001.

TRIMURTHI LIMITED

4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA.
Tel: 040 24757370, 29882220
Email : info@trimurthiltd.com
Website : www.trimurthiltd.com
CIN No : L67120TG1894R1C018956
Date: 09.02.2023

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 09.02.2023

Ref: Company's Letter dated 01.02.2023

Unit: Trimurthi Limited

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Trimurthi Limited** at its meeting held on Thursday, the 09th day of February 2023 at 11:00 a.m. at the registered office of the Company situated at 5-8-354/1106, Office No. 1106, Ratna Block, Raghav Ratna Towers, Chirag Ali Lane, Hyderabad - 500001, Telangana, approved the following:

1. Unaudited financial results for the quarter ended 31.12.2022. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the Quarter ended 31.12.2022. **(Enclosed)**

This is for the information and records of the Exchange, please.

The meeting concluded at 4:00 p.m.

Thanking you.

For Trimurthi Limited

Arun Kumar Bhangadia

Chairman and Managing Director
DIN: 00021024

Encl. as above

TRIMURTHI LIMITED
4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS
FOR THE QUARTER III AND NINE MONTHS ENDED 31ST DECEMBER 2022

PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31.12.2022 (UNAUDITED)	30.09.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.12.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.03.2022 (AUDITED)
1. INCOME						
INCOME FROM OPERATIONS	42.64	4.77	9.37	53.88	77.18	84.32
OTHER INCOME	18.27	4.43	6.36	28.52	46.06	55.17
TOTAL INCOME	60.91	9.19	15.93	82.20	123.24	139.49
2. EXPENSES						
PURCHASES	64.52	3.14	8.39	71.41	105.60	109.19
COST OF MATERIALS CONSUMED			-			
MANUFACTURING EXPENSES			-			
INCREASE/(DECREASE) IN STOCK IN TRADE	(24.74)	0.75	1.82	(24.19)	(33.81)	(28.37)
RENT	0.30	0.90	-	1.20	0.80	2.10
EMPLOYEE BENEFITS EXPENSE	6.87	7.07	6.71	20.71	19.61	29.10
FINANCE COSTS			-			
DEPRECIATION AND AMORTISATION EXPENSES	2.47	1.03	3.36	4.21	5.49	7.16
OTHER EXPENSES	4.96	4.24	3.71	16.12	19.31	178.88
TOTAL EXPENSES	54.38	17.13	23.99	89.46	117.00	296.06
3. PROFIT/(LOSS) FROM BEFORE EXCEPTIONAL ITEMS AND TAX (1-2)	6.53	(7.95)	(8.06)	(7.26)	6.24	(156.58)
4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS						
5. PROFIT/(LOSS) FROM CONTINUING OPERATIONS BEFORE TAX (3-4)	6.53	(7.95)	(8.06)	(7.26)	6.24	(156.58)
6. TAX EXPENSES	0.24	0.55	(6.78)	(0.10)	(0.58)	(0.55)
-CURRENT TAX			(3.39)			
-TAX ADJUSTMENTS RELATING TO EARLIER YEARS						
-DEFERRED TAX (NET)	0.24	0.55	(3.39)	(0.10)	(0.58)	(0.55)
7. NET PROFIT/(LOSS) FROM CONTINUING OPERATIONS AFTER TAX (5-6)	6.76	(8.50)	(1.28)	(7.36)	6.82	(156.03)
8. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS						
9. TAX EXPENSES FOR DISCONTINUED OPERATIONS						
10. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)						
11. PROFIT/(LOSS) FOR THE PERIOD (7+10)	6.76	(8.50)	(1.28)	(7.36)	6.82	(156.03)
12. OTHER COMPREHENSIVE INCOME						
A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS						
(a) INCOME TAX RELATING TO ITEM THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS						
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS						
(a) INCOME TAX RELATING TO ITEM THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS						
13. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT/(LOSS) AND OTHER COMPREHENSIVE INCOME)	6.76	(8.50)	(1.28)	(7.36)	6.82	(156.03)
14. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION) :						
(i) BASIC	0.08	(0.10)	(0.02)	(0.09)	0.08	(1.93)
(ii) DILUTED	0.08	(0.10)	(0.02)	(0.09)	0.08	(1.93)
15. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION) :						
(i) BASIC						
(ii) DILUTED						
16. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION) :						
(i) BASIC	0.08	(0.10)	(0.02)	(0.09)	0.08	(1.93)
(ii) DILUTED	0.08	(0.10)	(0.02)	(0.09)	0.08	(1.93)

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S, INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956



TRIMURTHI LIMITED

B-354/1106, Office No. 1106,
Rajna Block, Raghav Ratna Towers,
Chirag Ali Lane, Abid,
Hyderabad, Telangana - 500 031.

TRIMURTHI LIMITED



PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31.12.2022 (UNAUDITED)	30.09.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.12.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.03.2022 (AUDITED)
A. PARTICULARS OF SHARE HOLDING						
1. Public Share Holding						
- Number of Shares	2679267	2900600	2900600	2679267	2900600	2900600
- Percentage of shareholding	33.08%	35.81%	35.81%	33.08%	35.81%	35.81%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the shareholding of promoter and promoter group)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the total share capital of the company)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
b. Non encumbered						
- No of Equity Shares	5420733	5199400	5199400	5420733	5199400	5199400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	66.92%	64.19%	64.19%	66.92%	64.19%	64.19%

Particulars	3 Months Ended (31/12/2022)
B. Investor Complaints	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unresolved during the quarter	-NIL-

TRIMURTHI LIMITED

Segment Reporting

PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31.12.2022 (UNAUDITED)	30.09.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.12.2022 (UNAUDITED)	31.12.2021 (UNAUDITED)	31.03.2022 (AUDITED)
1. Segment Revenue						
a. Pharma Business	4.08	1.55	-	6.73		8.70
b. Financial Services	7.20	4.40	6.56	17.23	20.67	29.78
c. Investments	11.07	0.02	-	11.09	25.38	0.39
d. Trading in Shares	38.54	3.21	9.37	47.15	77.18	100.62
e. Foods	-	-	-	-	-	-
Total	60.91	9.19	15.93	82.20	123.23	139.49
Less: Inter Segment Revenue						
Net Sales/ Income From Operations	60.91	9.19	15.93	82.20	123.23	139.49
2. Segment Profits (Before tax & Interest From Each Segment)						
a. Pharma Business	-2.01	1.39	-	(0.46)		
b. Financial Services	7.20	4.40	6.56	17.23	20.67	15.05
c. Investments	11.07	0.02	-	11.09	25.38	(149.54)
d. Trading in Shares	-4.73	(13.77)	(14.62)	(35.12)	(39.82)	(22.89)
e. Foods	-	-	-	-	-	-
Total	6.53	(7.96)	(8.06)	(7.26)	6.23	(156.58)
Less:						
i. Interest						
ii. Other Un-allocable expenses net off						
iii. Un-allocable Income						
Total Profit Before Tax	6.53	(7.96)	(8.06)	(7.26)	6.23	(156.58)
3. Capital Employed						
a. Pharma Business	40.18	70.36	29.50	40.18	29.50	29.50
b. Financial Services	104.82	99.41	202.05	104.82	202.05	301.63
c. Investments	203.20	203.20	29.32	203.20	29.32	43.92
d. Trading in Shares	368.75	338.38	326.30	368.75	326.30	349.25
e. Foods	-	-	300.00	-	300.00	-
Total	716.95	711.35	887.17	716.95	887.17	724.30

Notes

- Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 09-02-2023
- The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.
- The results are also available on the website of the Company
- During the Quarter company has sold its 100% equity shares of Trimurthi Pharmaceuticals (India) Private limited, wholly owned subsidiary, as such it ceased to be the subsidiary of Trimurthi limited. The company has obtained the necessary consent from shareholders and complied the provisions of the companies Act, 2013.

Place: Hyderabad
Date: 09-02-2023

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

Arun K. Ramesh
Director

TRIMURTHI LIMITED
E-354/1106, Office No. 1106,
Ratna Block, Raghav Ratna Towers,
Chirag Ali Lane, Abid,
Hyderabad, Telangana - 500 001.



P.MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470

Fax : (91-40) 2339 2474

E-mail : pmurali.co@gmail.com
info@pmurali.com

Website : www.p murali .com

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review report to
The Board of Directors
Trimurthi Limited

We have reviewed the accompanying statement of unaudited financial results of **TRIMURTHI LIMITED** (the "Company") for the quarter ended 31st December, 2022 and for the period from 01 April 2022 to 31 December 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, (Ind AS 34,)' prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





P.MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470

Fax : (91-40) 2339 2474

E-mail : pmurali.co@gmail.com
info@pmurali.com

Website : www.pmurali.com

Emphasis of Matter Paragraph:

As disclosed in Note no. 5 to the financial results, During this quarter under review the company has sold its wholly owned subsidiary Trimurthi pharmaceuticals (India) private limited.

Our opinion is not modified in respect of the above matter.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S


A. Krishna Rao
Partner

M.No. 020085
UDIN: 23020085BGQWZN6016



Place: Hyderabad
Date: 09-02-2023.